免疫调节治疗的临床转化。
Clinical translation of immunomodulatory therapeutics.
机构信息
Rice University, Department of Bioengineering, Houston TX, United States.
Biologics Consulting, Inc, United States.
出版信息
Adv Drug Deliv Rev. 2021 Sep;176:113896. doi: 10.1016/j.addr.2021.113896. Epub 2021 Jul 27.
Immunomodulatory therapeutics represent a unique class of drug products that have tremendous potential to rebalance malfunctioning immune systems and are quickly becoming one of the fastest-growing areas in the pharmaceutical industry. For these drugs to become mainstream medicines, they must provide greater therapeutic benefit than the currently used treatments without causing severe toxicities. Immunomodulators, cell-based therapies, antibodies, and viral therapies have all achieved varying amounts of success in the treatment of cancers and/or autoimmune diseases. However, many challenges related to precision dosing, off-target effects, and manufacturing hurdles will need to be addressed before we see widespread adoption of these therapies in the clinic. This review provides a perspective on the progress of immunostimulatory and immunosuppressive therapies to date and discusses the opportunities and challenges for clinical translation of the next generation of immunomodulatory therapeutics.
免疫调节治疗药物代表了一类独特的药物产品，它们具有巨大的潜力来重新平衡功能失调的免疫系统，并且迅速成为制药行业发展最快的领域之一。为了使这些药物成为主流药物，它们必须提供比目前使用的治疗方法更大的治疗益处，而不会引起严重的毒性。免疫调节剂、细胞疗法、抗体和病毒疗法在癌症和/或自身免疫性疾病的治疗中都取得了不同程度的成功。然而，在我们广泛采用这些疗法之前，还需要解决与精确剂量、脱靶效应和制造障碍相关的许多挑战。本文综述了迄今为止免疫刺激和免疫抑制治疗的进展，并讨论了下一代免疫调节治疗药物临床转化的机遇和挑战。
Zotero 插件